Clinical Trial Update: Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078) [Phase 3]

View source ↗

Summary

A Phase 3 trial shows adding sitagliptin (Januvia) to metformin improves glycemic control in patients not adequately controlled on metformin.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Januvia (sitagliptin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Diabetes Mellitus, Non-Insulin-Dependent | Phase 3 | Status: COMPLETED | Results posted: 2011-05-11